4wf8: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==Crystal structure of NS3/4A protease in complex with Asunaprevir== | ==Crystal structure of NS3/4A protease in complex with Asunaprevir== | ||
<StructureSection load='4wf8' size='340' side='right' caption='[[4wf8]], [[Resolution|resolution]] 1.70Å' scene=''> | <StructureSection load='4wf8' size='340' side='right'caption='[[4wf8]], [[Resolution|resolution]] 1.70Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[4wf8]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4WF8 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4WF8 FirstGlance]. <br> | <table><tr><td colspan='2'>[[4wf8]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/9hepc 9hepc]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4WF8 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4WF8 FirstGlance]. <br> | ||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=2R9:N-(TERT-BUTOXYCARBONYL)-3-METHYL-L-VALYL-(4R)-4-[(7-CHLORO-4-METHOXYISOQUINOLIN-1-YL)OXY]-N-{(1R,2S)-1-[(CYCLOPROPYLSULFONYL)CARBAMOYL]-2-ETHENYLCYCLOPROPYL}-L-PROLINAMIDE'>2R9</scene>, <scene name='pdbligand=CL:CHLORIDE+ION'>CL</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr> | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=2R9:N-(TERT-BUTOXYCARBONYL)-3-METHYL-L-VALYL-(4R)-4-[(7-CHLORO-4-METHOXYISOQUINOLIN-1-YL)OXY]-N-{(1R,2S)-1-[(CYCLOPROPYLSULFONYL)CARBAMOYL]-2-ETHENYLCYCLOPROPYL}-L-PROLINAMIDE'>2R9</scene>, <scene name='pdbligand=CL:CHLORIDE+ION'>CL</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4wf8 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4wf8 OCA], [http://pdbe.org/4wf8 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4wf8 RCSB], [http://www.ebi.ac.uk/pdbsum/4wf8 PDBsum]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4wf8 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4wf8 OCA], [http://pdbe.org/4wf8 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4wf8 RCSB], [http://www.ebi.ac.uk/pdbsum/4wf8 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4wf8 ProSAT]</span></td></tr> | ||
</table> | </table> | ||
<div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
| Line 19: | Line 20: | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: Large Structures]] | |||
[[Category: Ali, A]] | [[Category: Ali, A]] | ||
[[Category: Schiffer, C A]] | [[Category: Schiffer, C A]] | ||
Revision as of 11:15, 23 May 2019
Crystal structure of NS3/4A protease in complex with AsunaprevirCrystal structure of NS3/4A protease in complex with Asunaprevir
Structural highlights
Publication Abstract from PubMedAsunaprevir (ASV), an isoquinoline-based competitive inhibitor targeting the hepatitis C virus (HCV) NS3/4A protease, is very potent in vivo. However, the potency is significantly compromised by the drug resistance mutations R155K and D168A. In this study three crystal structures of ASV and an analogue were determined to analyze the structural basis of drug resistance susceptibility. These structures revealed that ASV makes extensive contacts with Arg155 outside the substrate envelope. Arg155 in turn is stabilized by Asp168, and thus when either residue is mutated, the enzyme's interaction with ASV's P2* isoquinoline is disrupted. Adding a P1-P3 macrocycle to ASV enhances the inhibitor's resistance barrier, likely due to poising the inhibitor to its bound conformation. Macrocyclic inhibitors with P2* extension moieties avoiding interaction with the protease S2 residues including Arg155 must be chosen for future design of more robust protease inhibitors. Structural Analysis of Asunaprevir Resistance in HCV NS3/4A Protease.,Soumana DI, Ali A, Schiffer CA ACS Chem Biol. 2014 Sep 30. PMID:25243902[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. References
|
| ||||||||||||||||